Shots: The CHRYSALIS study involves assessing amivantamab as a monothx. and in combination with Lazertinib in 460 patients with advanced NSCLC with various EGFR mutations The updated data showed mDOR […]readmore
Tags : EGFR-Mutated NSCLC
Shots: The P-II HERTHENA-Lung01 study involves assessing patritumab deruxtecan in 420 patients in a ratio (1:1) with EGFR-mutated m/ LA NSCLC prior treated with TKI and Pt-based CT. The first […]readmore